Liposome longevity and stability in circulation : Effects of the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclinesGABIZON, A; CHEMLA, M; TZEMACH, D et al.Journal of drug targeting. 1996, Vol 3, Num 5, pp 391-398, issn 1061-186XArticle

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinomaLYASS, O; UZIELY, B; BEN-YOSEF, R et al.Cancer. 2000, Vol 89, Num 5, pp 1037-1047, issn 0008-543XArticle

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomesSYMON, Z; PEYSER, A; TZEMACH, D et al.Cancer. 1999, Vol 86, Num 1, pp 72-78, issn 0008-543XArticle

Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma modelCABANES, A; TZEMACH, D; GOREN, D et al.Clinical cancer research. 1998, Vol 4, Num 2, pp 499-505, issn 1078-0432Article

Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animalsGABIZON, A; GOREN, D; HOROWITZ, A. T et al.Advanced drug delivery reviews. 1997, Vol 24, Num 2-3, pp 337-344, issn 0169-409XConference Paper